The Importance of HIPAA Compliant Technologies in the MMJ Industry

SUMMARY: Germany is the fifth largest B2C ecommerce market in the world. If you want to expand your business into this large and growing market, what do you need to know about the preferences of German shoppers? 

Watch our interview with Nadine Späth, Manager of Consumer Markets and Ecommerce, Germany Trade & Invest, to learn more about how German financial and cultural preferences differ from those of American consumers.

In January 2015, BEVH, the German Ecommerce and Distance Selling Trade Association, conducted an online survey with Creditreform Boniversum asking a representative sample of 1,054 German shoppers, 18 to 69 years old, about their online payment habits. 
 

Pennsylvania drugmaker Zynerba Pharmaceuticals ($ZYNE) is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.

The company priced 3 million shares at $14 each, the middle of its range, and set aside another 450,000 shares for its underwriters to line up for as much as $51.8 million in total.

Cannabis Reports has released the most powerful open cannabis API (application programming interface), providing access to an ever-growing list of over 16,000 strains, extracts, edibles, products, producers, seed companies, and dispensaries. “We are thrilled to be providing the cannabis community with improved information technology,” says David Drake, Founder & CEO of Cannabis Reports.

“We believe information can be one of the most powerful forces in ensuring an open and free industry where everyone can thrive on an equal playing field,” continues Drake. “That's why we're offering an API to let our cannabis community build upon the years of work we've done to catalogue and organize this fast evolving industry.”

Cutting-edge medical research often calls for support from science-literate lawyers, no more so than in the legalisation of contentious drugs, such as medicinal marijuana, says Dr Teresa Nicoletti.

Dr Nicoletti (pictured) is a partner at Piper Alderman who is currently advising players in the emerging medicinal cannabis industry in Australia. 

She spoke with Lawyers Weekly following an important breakthrough: the approval of a new medicinal cannabis trial by NSW Premier Mike Baird last week.

Zynerba Pharmaceuticals (ZYNE) released a public offering outlining its plans to roll out their pipeline of cannabinoid-based drugs. Zynerba is exploring the first controlled-delivery system for cannabinoids. The novelty of a transdermal patch has picked up steam and investor excitement in the pharmaceutical cannabis sector. However, an FDA approval is absolutely crucial for the success of any major pharmaceutical drug.

A US start-up is awaiting the regulatory green light to deliver marijuana direct to smokers doors via drones.

Trees Delivery, which hopes to get the go ahead to start its service in California, will allow its customers to place orders through their phone or computer, pay with virtual currency Bitcoin and receive their goods almost instantly.

San Francisco-based Trees offers three 'boxes': the bud box, which includes exotic and hard to find strains, the extract box, which contains hash, and a beginner box.

The boxes also contain accessories such as paper and filter tips, grinders, lighters and rolling papers.

The catch? Smokers must have a medical license to order marijuana under the law.

The U.S. may be the largest medical cannabis market in the world with sales exceeding $65 billion in 2014 and projections for 2015 surpassing that, but Israel is at the heart of much of the world’s leading medical cannabis research. After all, the Startup Nation has been at it since the 1960s.

Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.

Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.

Right now, we're going to see how it's performed, but, even better, how to maximize the "free trade" it's about to give us.

And if you missed this stock last year – no worries. We'll start you now as it continues its run – a run that took off while "popular" medical marijuana stocks cratered.

Here's how we'll do it…